Which heart valve prosthesis for patients aged between 60 and 70 years?

Heart

Volumn 89, Issue 5, 2003, Pages 481-482

  Hanania, Guy ^a  

^a Centre Hospitalier Robert Ballanger CHRB   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

AGE DISTRIBUTION; BIOPROSTHESIS; BLEEDING TENDENCY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG CONTRAINDICATION; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MORBIDITY; PATIENT ATTITUDE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037406348     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.5.481     Document Type: Review

References (11)

1. Bonow RO, Carabello B, de Leon AC Jr, et al. ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 1998;32:1486-588.
2. Bloomfield P, Wheatley DJ, Prescott RJ, et al. Twelve-year comparison of a Bjark-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med 1991;324:573-9.
3. Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000;36:1152-8.
4. Hanania G, Michel PL, Montely JM, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve in patients between 60 and 70 years of age. J Am Coll Cardiol 2002;39(suppl A):423A.
5. Holper K, Wottke M, Lewe T, et al. Bioprosthetic and mechanical valves in the elderly: benefits and risks. Ann Thorac Surg 1995;60(suppl. 2):S443-6.
6. Emery RW, Arom KV, Kshettry VR. Decision-making in the choice of heart valve for replacement in patients aged 60-70 years: twenty-year follow up of the St. Jude Medical Aortic Valve Prosthesis. J Heart Valve Dis 2002;11(suppl I):S37-44.
7. Gohlke-Barwolf C, Acar J, Oakley C, et al. Guidelines for prevention of thromboembolic events in valvular heart diseases: study group of the working group on valvular heart disease of the European Society of Cardiology. Eur Heart J 1995;16:1320-30.
8. Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996;94:2107-12.
9. Rosengart TK. Anticoagulation self testing after heart valve replacement. J Heart Valve Dis 2002;11(suppl. I):S61-5.
10. Khan S. Long-term outcomes with mechanical and tissue valves. J Heart Valve Dis 2002;11(suppl 1):S8-14.
11. Dalrymple-Hay MJR, Crook T, Bannon PG, et al. Risk of reoperation for structural failure of aortic and mitral tissue valves. J Heart Valve Dis 2002;11:419-23.